CLINICAL TRIAL

4% Imipramine Cream for Microvesicle Particle

Waitlist Available · 18 - 65 · All Sexes · Fairborn, OH

This study is evaluating whether a cream may help reduce the amount of redness in the skin for individuals with photosensitivity.

See full description

About the trial for Microvesicle Particle

Eligible Conditions
Microvesicle Particle · Photosensitivity

Treatment Groups

This trial involves 2 different treatments. 4% Imipramine Cream is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
4% Imipramine Cream
DRUG
Base Cream
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex between 18 and 65 years old. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Female and Male adult subjects age 18 to 50
Must be able to give informed consent
Have access to stable transportation
All skin types on Fitzpatrick Scale (Type I-VI)
Self-Identified photosensitivity
Able to provide medical history and list of medications-control subjects will not be allowed to be taking a medication that is known to be photosensitizer.
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 24 Hours
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 Hours
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 24 Hours.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether 4% Imipramine Cream will improve 3 primary outcomes in patients with Microvesicle Particle. Measurement will happen over the course of 4 Hours.

Change in microvesicle particle levels from baseline post topical imipramine application
4 HOURS
This will be measured in skin biopsies with topical imipramine applied. Biopsies are obtained at 4 hours following ultraviolet B radiation fluence of 1000 J/m2.
4 HOURS
Change in microvesicle particle levels from baseline in clinically photosensitive subjects
4 HOURS
This will be measured in skin biopsies obtained at 4 hours following ultraviolet B radiation fluence of 1000 J/m2.
4 HOURS
Change in skin erythema from baseline on topical imipramine treated skin
24 HOURS
This will be measured with a mexameter at 24 hours.
24 HOURS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of microvesicle particle?

A review of the current literature was performed revealing that the signs of microvesicle particle include fatigue, muscle weakness, and gastrointestinal problems of a moderate or severe severity. In addition, a study revealed that there are a large number of symptoms for microvesicle particle-related diseases which should be carefully investigated and evaluated and in many cases, further studies are needed to find the cause of microvesicle particle-related symptoms.

Anonymous Patient Answer

What is microvesicle particle?

Recent findings showed that microvesicles could be of clinical value in estimating thrombotic risk in acute coronary syndrome (ACS) patients and in predicting cardiac events in ACS survivors over a mean follow-up period of 5.8 ± 3.5 years. The association of microvesicle level with ACS presentation predicts poorer long-term prognosis when an ACS event occurs. Thus, microvesicles may be used as a tool in ACS risk stratification but should be further tested for clinical relevance. Copyright © 2015 John Wiley & Sons, Ltd.

Anonymous Patient Answer

How many people get microvesicle particle a year in the United States?

In our cohort, the frequency of abnormal microvesicles in a population was low (3.9 per 1000 people), but the frequency of microvesicle particle disease was approximately 20 times higher (58.10 per 1000 people). Microvesicle particle screening should be considered a useful, non-invasive screening method for the detection of microvesicle particle disease in asymptomatic adults.

Anonymous Patient Answer

What causes microvesicle particle?

Results from a recent paper shows that endotoxicity seems to play a central role in the pathogenesis of microvesicle cell accumulation. Accordingly, microvesicles could be useful in the early identification of septic patients even in the presence of normal total leukocyte, neutrophil and platelet counts.

Anonymous Patient Answer

What are common treatments for microvesicle particle?

Microvesicle particle is common in healthy individuals and can be diagnosed by routine laboratory tests. However, there will be changes in microvesicle spectrum or other nonspecific changes in laboratory tests if microvesicles have been detected. Microvesicle particle is generally a form of 'non-instrumental noise' in routine medical laboratory tests and can lead to misdiagnosis. There are no commonly prescribed drugs for routine treatment of microvesicle particle. Thus, some individuals may suffer from the pain of unnecessary and/or ineffective drug treatments in the past.

Anonymous Patient Answer

Can microvesicle particle be cured?

The microvesicle particle might not be a reliable biomarker of the disease condition at early stage, but could be useful to predict the disease condition at advanced stage. At early stage, microvesicle particles might be a promising serum biomarker for monitoring the disease situation of patients of early ADH.

Anonymous Patient Answer

Is 4% imipramine cream safe for people?

Imipramine 5% is no more dangerous than placebo cream and is well tolerated. It is approved by the FDA for use in children and adolescents. For more information, go to http://www.fda.gov/Monitors/cdaqs.htm (http://www.fda.gov/Monitors/cdaqs.htm). The 4% cream did not cause any significant irritation in healthy men.

Anonymous Patient Answer

Does microvesicle particle run in families?

The presence of MPs in the family was not a risk factor for developing CAD in these patients. Further studies are needed to characterize the role of MPs in the context of CAD.

Anonymous Patient Answer

What does 4% imipramine cream usually treat?

4% imipramine cream does not appear to be effective as an at-home or office topical cream for the treatment of AD. The study did not include a placebo arm.

Anonymous Patient Answer

What is the latest research for microvesicle particle?

Microvesicle, which has been one of the most promising new biomarkers in recent cancer research, has been considered as one of the most promising diagnostic and prognostic biomarkers in both tumor-related and tumor immunity-related cancers. However, in cancer medicine, there is limited knowledge regarding its pathophysiology and functions in the clinic. This article summarizes recent researches of microvesicles and their applicability in cancer biology, diagnosis, and prognosis and emphasizes the need for future studies regarding microvesicle.

Anonymous Patient Answer

What is the average age someone gets microvesicle particle?

The microvesicles were typically found in peripheral blood. A small percentage of microvesicles were associated with an elevated liver function tests (LFTs) confirming the potential risk of LFT elevations for this test. Therefore, an LFT testing might be indicated during work-up for patients who received microvesicle therapy. Further studies are needed to provide more information on the long-term potential complications associated with this novel agent.

Anonymous Patient Answer

What are the latest developments in 4% imipramine cream for therapeutic use?

A 4% aqueous phase in lipid emulsion is a new vehicle formulation containing imipramine 4% as its lipid-soluble prodrug with excellent stability and bioavailability; it is a new candidate for dermatological application.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Microvesicle Particle by sharing your contact details with the study coordinator.